The USPTO granted a patent for IHL-42X, a proprietary oral combination therapy for obstructive sleep apnoea (OSA). The patent provides intellectual property protection until at least July 9, 2040. The company is exploring potential patent term extensions following future FDA approval. The DReAMzz dose optimisation study is nearing the patient recruitment phase, with IRB approvals and DEA registrations in progress.